

DAFTAR PUSTAKA

- Alzheimer Association. 2025. Alzheimer's Disease Facts and Figures. In *Alzheimer Association*. <https://www.alz.org/getmedia/ef8f48f9-ad36-48ea-87f9-b74034635c1e/alzheimers-facts-and-figures.pdf>
- Arenare, G., Manca, R., Caffarra, P., & Venneri, A. 2023. Associations between Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers in People with Mild Cognitive Impairment. *Brain Sciences*, 13(8), 1195. <https://doi.org/10.3390/brainsci13081195>
- Babulal, G. M., Ghoshal, N., Head, D., Vernon, E. K., Holtzman, D. M., Benzinger, T. L. S., Fagan, A. M., Morris, J. C., & Roe, C. M. 2016. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. *The American Journal of Geriatric Psychiatry*, 24(11), 1095–1104. <https://doi.org/10.1016/j.jagp.2016.04.004>
- Banning, L. C. P., Ramakers, I. H. G. B., Köhler, S., Bron, E. E., Verhey, F. R. J., de Deyn, P. P., Claassen, J. A. H. R., Koek, H. L., Middelkoop, H. A. M., van der Flier, W. M., van der Lugt, A., & Aalten, P. 2020. The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum. *The American Journal of Geriatric Psychiatry*, 28(7), 735–744. <https://doi.org/10.1016/j.jagp.2020.01.012>
- Barron, M., Gartlon, J., Dawson, L. A., Atkinson, P. J., & Pardon, M. C. 2017. A state of delirium: Deciphering the effect of inflammation on tau pathology in Alzheimer's disease. *Experimental Gerontology*, 94(June), 103–107. <https://doi.org/10.1016/j.exger.2016.12.006>
- Bessey, L. J., & Walaszek, A. 2019. Management of Behavioral and Psychological Symptoms of Dementia. *Current Psychiatry Reports*, 21(8), 66. <https://doi.org/10.1007/s11920-019-1049-5>
- Bickel, H., Hendlmeier, I., Heßler, J. B., Junge, M. N., Leonhardt-Achilles, S., Weber, J., & Schäufele, M. 2018. The Prevalence of Dementia and Cognitive Impairment in Hospitals. *Deutsches Ärzteblatt international*. <https://doi.org/10.3238/arztebl.2018.0733>
- Castellani, R. J. 2020. The significance of tau aggregates in the human brain. *Brain Sciences*, 10(12), 1–14. <https://doi.org/10.3390/brainsci10120972>
- Celis, K., Zaman, A., Adams, L. D., Gardner, O., Farid, R., Starks, T. D., Lacroix, F. C., Hamilton-Nelson, K., Mena, P., Tejada, S., Laux, R., Song, Y. E., Caban-Holt, A., Feliciano-Astacio, B., Vance, J. M., Haines, J. L., Byrd, G. S., Beecham, G. W., Pericak-Vance, M. A., & Cuccaro, M. L. 2023. Neuropsychiatric features in a multi-ethnic population with Alzheimer disease and mild cognitive impairment. *International Journal of Geriatric Psychiatry*, 38(9), 1–17. <https://doi.org/10.1002/gps.5992>
- Cerejeira, J., Lagarto, L., & Mukaetova-Ladinska, E. B. 2012. Behavioral and psychological symptoms of dementia. *Frontiers in Neurology*, MAY(May), 1–21. <https://doi.org/10.3389/fneur.2012.00073>

- Chang, C. Y., Lan, S. J., Chu, C. L., & Ho, C. S. 2021. The relationship between clinic visit accompanied by family and dementia severity in Taiwan. *International Journal of Environmental Research and Public Health*, 18(4), 1–9. <https://doi.org/10.3390/ijerph18041792>
- Cloak, N. ;, & Al Khalili, Y. . 2022. *Behavioral and Psychological Symptoms in Dementia*. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK551552/>
- Cooper, J. G., Stukas, S., Ghodsi, M., Ahmed, N., Diaz-Arrastia, R., Holmes, D. T., & Wellington, C. L. 2023. Age specific reference intervals for plasma biomarkers of neurodegeneration and neurotrauma in a Canadian population. *Clinical Biochemistry*, 121–122(August), 110680. <https://doi.org/10.1016/j.clinbiochem.2023.110680>
- Cummings, J. L., & Back, C. 1998. The Cholinergic Hypothesis of Neuropsychiatric Symptoms in Alzheimer's Disease. *The American Journal of Geriatric Psychiatry*, 6(2), S64–S78. <https://doi.org/10.1097/00019442-199821001-00009>
- Cummings, J., Megan, M., Gray, K., Rosenberg-Thompson, S., Carusi, D., & Gornbein, J. 2000. The neuropsychiatric inventory questionnaire: comprehensive assessment of psychopathology in patients with Dementia. *J Neuropsychiatry Clin Neurosci*, 12, 233–239.
- Dahlan, M. S. 2010. *Besar Sampel Dan Cara Pengambilan Sampel*. Salemba Medika.
- De Strooper, B., & Karran, E. 2016. The Cellular Phase of Alzheimer's Disease. *Cell*, 164(4), 603–615. <https://doi.org/10.1016/j.cell.2015.12.056>
- Deo, V. K., Singh, K. K., Sinha, N., Kumar, A., & Kumar, S. 2024. Correlation of behavioral and psychological symptoms of dementia with patients' sociodemographic & clinical details and caregivers' distress. *Industrial Psychiatry Journal*, 33(1), 101–107. https://doi.org/10.4103/ipj.ipj_137_23
- Dikot, Y., & Fransisca, R. 2022. *Buku Referensi Neurobehavior Klinis* (P. Prawiroharjo, Astuti, & S. B. Rianawati (ed.); 1 ed.). PT Ilmiah Mutakhir Indonesia.
- Farina, N., Jacobs, R., Turana, Y., Fitri, F. I., Schneider, M., Theresia, I., Docrat, S., Sani, T. P., Augustina, L., Albanese, E., Comas-Herrera, A., Du Toit, P., Ferri, C. P., Govia, I., Ibnidris, A., Knapp, M., & Banerjee, S. 2023. Comprehensive measurement of the prevalence of dementia in low- and middle-income countries: STRiDE methodology and its application in Indonesia and South Africa. *BJPsych Open*, 9(4), 1–7. <https://doi.org/10.1192/bjo.2023.76>
- Ghahremani, M., Wang, M., Chen, H. Y., Zetterberg, H., Smith, E., & Ismail, Z. 2023. Plasma Phosphorylated Tau at Threonine 181 and Neuropsychiatric Symptoms in Preclinical and Prodromal Alzheimer Disease. *Neurology*, 100(7), E683–E693. <https://doi.org/10.1212/WNL.0000000000201517>

- Godinho, C., Gorczewski, I., Heisler, A., Cerveira, M. O., & Chaves, M. L. 2010. Características clínicas e demográficas de pacientes idosos com demência atendidos em uma clínica do sul do Brasil. *Dementia e Neuropsychologia*, 4(1), 42–46. <https://doi.org/10.1590/S1980-57642010DN40100007>
- Gonzales, M. M., Insel, P. S., Nelson, C., Tosun, D., Schöll, M., Mattsson, N., Sacuiu, S., Bickford, D., Weiner, M. W., & Mackin, R. S. 2018. Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment. *International Journal of Geriatric Psychiatry*, 33(10), 1305–1311. <https://doi.org/10.1002/gps.4926>
- González, D. A., Finley, J.-C. A., Patel, S. E. S., & Soble, J. R. 2025. Practical Assessment of Neuropsychiatric Symptoms: Updated Reliability, Validity, and Cutoffs for the Neuropsychiatric Inventory Questionnaire. *The American Journal of Geriatric Psychiatry*, 33(5), 524–534. <https://doi.org/10.1016/j.jagp.2024.10.014>
- Grande, G., Valletta, M., Rizzuto, D., Xia, X., Qiu, C., Orsini, N., Dale, M., Andersson, S., Fredolini, C., Winblad, B., Laukka, E. J., Fratiglioni, L., & Vetrano, D. L. 2025. Blood-based biomarkers of Alzheimer's disease and incident dementia in the community. *Nature Medicine*, 31(6), 2027–2035. <https://doi.org/10.1038/s41591-025-03605-x>
- Granhölm, A. C., & Hamlett, E. D. 2024. The Role of Tau Pathology in Alzheimer's Disease and Down Syndrome. *Journal of Clinical Medicine*, 13(5). <https://doi.org/10.3390/jcm13051338>
- Huang, S. S., Wang, W. F., & Liao, Y. C. 2017. Severity and prevalence of behavioral and psychological symptoms among patients of different dementia stages in taiwan. *Revista de Psiquiatria Clinica*, 44(4), 89–93. <https://doi.org/10.1590/0101-60830000000127>
- Husein, N., Lumempouw, S. F., Ramli, Y., & Herqutanto. 2010. MONTREAL COGNITIVE ASSESSMENT VERSI INDONESIA MoCAIna UNTUK SKRINING GANGGUAN FUNGSI KOGNITIF. *Neurona*, 27(4). <https://arsip.neurona.web.id/paper/734.pdf>
- International Psychogeriatric Association. 2015. The IPA Complete Guides to Behavioral and Psychological Symptoms of Dementia The IPA Complete Guides to Behavioral and Psychological Symptoms of Dementia (BPSD) The IPA Complete Guides to. *The BPSD Educational Pack*.
- Janelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., Blennow, K., Reiman, E. M., Stomrud, E., Dage, J. L., & Hansson, O. 2020. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. *Nature Medicine*, 26(3), 379–386. <https://doi.org/10.1038/s41591-020-0755-1>
- Javadi, S. F., Giebel, C., Khan, M. A., & Hashim, M. J. 2021. Epidemiology of Alzheimer's disease and other dementias: rising global burden and forecasted trends. *F1000Research*, 10, 425. <https://doi.org/10.12688/f1000research.50786.1>

- Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. 2021. Alzheimer disease. *Nature Reviews Disease Primers*, 7(1), 33. <https://doi.org/10.1038/s41572-021-00269-y>
- Kovacs, G. G. 2019. Molecular pathology of neurodegenerative diseases: Principles and practice. *Journal of Clinical Pathology*, 72(11), 725–735. <https://doi.org/10.1136/jclinpath-2019-205952>
- Krell-Roesch, J., Zaniletti, I., Syrjanen, J. A., Kremers, W. K., Algeciras-Schimmich, A., Dage, J. L., van Harten, A. C., Fields, J. A., Knopman, D. S., Jack, C. R., Petersen, R. C., Vassilaki, M., & Geda, Y. E. 2023. Plasma-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: A community-based study. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, 15(3), 1–11. <https://doi.org/10.1002/dad2.12461>
- Kumar, A., Sidhu, J. J., Goyal, A., & Tsao, J. W. 2022. *Alzheimer Disease*. StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK499922/>
- Laganà, V., Bruno, F., Altomari, N., Bruni, G., Smirne, N., Curcio, S., Mirabelli, M., Colao, R., Puccio, G., Frangipane, F., Cupidi, C., Torchia, G., Muraca, G., Malvaso, A., Addesi, D., Montesanto, A., Di Lorenzo, R., Bruni, A. C., & Maletta, R. 2022. Neuropsychiatric or Behavioral and Psychological Symptoms of Dementia (BPSD): Focus on Prevalence and Natural History in Alzheimer's Disease and Frontotemporal Dementia. *Frontiers in Neurology*, 13. <https://doi.org/10.3389/fneur.2022.832199>
- Lancôt, K. L., Boada, M., Tariot, P. N., Dabbous, F., Hahn-Pedersen, J., Udayachalerm, S., Raket, L. L., Saiontz-Martinez, C., Michalak, W., Weidner, W., & Cummings, J. 2024. Association between clinical dementia rating and clinical outcomes in Alzheimer's disease. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring*, 16(1). <https://doi.org/10.1002/dad2.12522>
- Li, X., Feng, X., Sun, X., Hou, N., Han, F., & Liu, Y. 2022. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2019. *Frontiers in Aging Neuroscience*, 14. <https://doi.org/10.3389/fnagi.2022.937486>
- Li, X., Song, D., & Leng, S. X. 2015. Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment. *Clinical interventions in aging*, 10, 549–560. <https://doi.org/10.2147/CIA.S74042>
- Liang, C., Yan, X., Tian, J., Yang, Y., Xiao, X., Huang, Y., & Wang, T. 2025. Plasma GFAP, NfL, and p-tau181 levels as early biomarkers of dementia in Chinese adults: Shenzhen community cohort study. *Aging Clinical and Experimental Research*, 37(1), 1–8. <https://doi.org/10.1007/s40520-025-03001-y>
- Ma, H., Lu, X., Zhou, A., Wang, F., Zuo, X., Zhan, M., Zou, Q., Gong, S., Chen, Y., Lyu, J., Jia, L., Jia, J., & Wei, C. 2022. Clinical Practice Guidelines for the Management of Behavioral and Psychological Symptoms of Dementia: A Systematic Review With AGREE II. *Frontiers in Neurology*, 13(May).

<https://doi.org/10.3389/fneur.2022.799723>

- Mashal, Y., Abdelhady, H., & Iyer, A. K. 2022. Comparison of Tau and Amyloid- β Targeted Immunotherapy Nanoparticles for Alzheimer's Disease. *Biomolecules*, 12(7). <https://doi.org/10.3390/biom12071001>
- Maslim, R. 2013. *Diagnosis Gangguan Jiwa, Rujukan Ringkas PPDGJ-III dan DSM-5*. PT Nuh Jaya - Jakarta.
- McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., Mohs, R. C., Morris, J. C., Rossor, M. N., Scheltens, P., Carrillo, M. C., Thies, B., Weintraub, S., & Phelps, C. H. 2011. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's and Dementia*, 7(3), 263–269. <https://doi.org/10.1016/j.jalz.2011.03.005>
- Mendez, M. F. 2019. Early-onset Alzheimer disease and its variants. *CONTINUUM Lifelong Learning in Neurology*, 25(1), 34–51. <https://doi.org/10.1212/CON.0000000000000687>
- Meng, J., & Lei, P. 2020. Plasma pTau181 as a biomarker for Alzheimer's disease. *MedComm*, 1(1), 74–76. <https://doi.org/10.1002/mco2.1>
- Michalicova, A., Majerova, P., & Kovac, A. 2020. Tau Protein and Its Role in Blood–Brain Barrier Dysfunction. *Frontiers in Molecular Neuroscience*, 13. <https://doi.org/10.3389/fnmol.2020.570045>
- Mielke, M. M., Hagen, C. E., Xu, J., Chai, X., Vemuri, P., Lowe, V. J., Airey, D.C., Knopman, D. S., Roberts, R. O., Machulda, M. M., Jack, C. R., Petersen, R. C., & Dage, J. L. 2018. Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography. *Alzheimer's & Dementia*, 14(8), 989–997. <https://doi.org/10.1016/j.jalz.2018.02.013>
- Minger, S. L., Esiri, M. M., McDonald, B., Keene, J., Carter, J., Hope, T., & Francis, P. T. 2000. Cholinergic deficits contribute to behavioral disturbance in patients with dementia. *Neurology*, 55(10), 1460–1467. <https://doi.org/10.1212/WNL.55.10.1460>
- Mokhtar, S. H., Bakhuraysah, M. M., Cram, D. S., & Petratos, S. 2013. The Beta-Amyloid Protein of Alzheimer's Disease: Communication Breakdown by Modifying the Neuronal Cytoskeleton. *International Journal of Alzheimer's Disease*, 2013, 1–15. <https://doi.org/10.1155/2013/910502>
- Morris, J. C. 1993. The clinical dementia rating (cdr): Current version and scoring rules. *Neurology*, 43(11), 2412–2414. <https://doi.org/10.1212/wnl.43.11.2412-a>
- Moscoso, A., Grothe, M. J., Ashton, N. J., Karikari, T. K., Rodriguez, J. L., Snellman, A., Suárez-Calvet, M., Zetterberg, H., Blennow, K., & Schöll, M. 2021. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. *Brain*, 144(1), 325–339. <https://doi.org/10.1093/brain/>

- Murda, B. K. K. 2023. Uji Validitas dan Reliabilitas Instrumen Neuropsychiatric Inventory Questionnaire Versi Bahasa Indonesia. In *Universitas Sebelas Maret: Vol. (Nomor)*. Universitas Sebelas Maret.
- Murray, B., Shaw, H., & Macdonald, O. 2019. *Guidelines for the management of Behavioural and Psychological Symptoms of Dementia (BPSD)*. March. [www.oxfordhealthformulary.nhs.uk/docs/OHFT BPSD Guideline May 2019.pdf](http://www.oxfordhealthformulary.nhs.uk/docs/OHFT_BPSD_Guideline_May_2019.pdf)
- Ng, K. P., Chiew, H., Rosa-Neto, P., Kandiah, N., Ismail, Z., & Gauthier, S. 2021. Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer's disease and cognitively unimpaired individuals. *Translational Neurodegeneration*, 10(1). <https://doi.org/10.1186/s40035-021-00236-3>
- Nugraha, S., Tondokoro, T., Susilowati, I. H., Hasiholan, B. P., Alimoeso, S., Rahardjo, T. B. W., Takagi, K., & Wada, K. 2022. Knowledge about Dementia and its Associated Factors: Study among the Middle-aged Population in Indonesia. *Open Access Macedonian Journal of Medical Sciences*, 10(E), 783–789. <https://doi.org/10.3889/oamjms.2022.8892>
- Pacholko, A., & Iadecola, C. 2024. Hypertension, Neurodegeneration, and Cognitive Decline. *Hypertension*, 81(5), 991–1007. <https://doi.org/10.1161/HYPERTENSIONAHA.123.21356>
- Panza, F., Frisardi, V., Seripa, D., D'Onofrio, G., Santamato, A., Masullo, C., Logroscino, G., Solfrizzi, V., & Pilotto, A. 2012. Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease. *Ageing Research Reviews*, 11(1), 87–103. <https://doi.org/10.1016/j.arr.2011.06.005>
- Paterno, G., Bell, B. M., Gorion, K. M. M., Prokop, S., & Giasson, B. I. 2022. Reassessment of Neuronal Tau Distribution in Adult Human Brain and Implications for Tau Pathobiology. *Acta Neuropathologica Communications*, 10(1), 1–14. <https://doi.org/10.1186/s40478-022-01394-9>
- Peng, C., Trojanowski, J. Q., & Lee, V. M.-Y. 2020. Protein transmission in neurodegenerative disease. *Nature Reviews Neurology*, 16(4), 199–212. <https://doi.org/10.1038/s41582-020-0333-7>
- Perdossi. 2015. *Panduan Praktik Klinik Diagnosis dan Penatalaksanaan Demensia*.
- Rabl, M., Zullo, L., Lewczuk, P., Kornhuber, J., Karikari, T. K., Blennow, K., Zetterberg, H., Bavato, F., Quednow, B. B., Seifritz, E., von Gunten, A., Clark, C., & Popp, J. 2024. Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression. *Alzheimer's Research and Therapy*, 16(1), 1–11. <https://doi.org/10.1186/s13195-024-01526-4>
- Rawat, P., Sehar, U., Bisht, J., Selman, A., Culberson, J., & Reddy, P. H. 2022. Phosphorylated Tau in Alzheimer's Disease and Other Tauopathies.

- International Journal of Molecular Sciences*, 23(21).
<https://doi.org/10.3390/ijms232112841>
- Rizzi, L., Rosset, I., & Roriz-Cruz, M. 2014. Global epidemiology of dementia: Alzheimer's and vascular types. *BioMed Research International*, 2014(Figure 1). <https://doi.org/10.1155/2014/908915>
- Ropper, A. H., Samuels, M. A., Klein, J. P., & Prasad, S. 2023. Adams and Victor's Principles of Neurology. In *Adams and Victor's Principles of Neurology*, 12e (12th ed., h. 575). McGraw-Hill Education. <http://accessmedicine.mhmedical.com/content.aspx?aid=1199439582>
- Sachdev, P. S., Blacker, D., Blazer, D. G., Ganguli, M., Jeste, D. V., Paulsen, J. S., & Petersen, R. C. 2014. Classifying neurocognitive disorders: The DSM-5 approach. *Nature Reviews Neurology*, 10(11), 634–642. <https://doi.org/10.1038/nrneurol.2014.181>
- Saldanha, D., Mani, R. N., Mujawar, S., & Chaudhury, S. 2021. A study of dementia in old age homes. *Industrial Psychiatry Journal*, 30(Suppl 1), S149–S154. <https://doi.org/10.4103/0972-6748.328806>
- Samudra, N., Lane-Donovan, C., VandeVrede, L., & Boxer, A. L. 2023. Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues. *Journal of Clinical Investigation*, 133(12). <https://doi.org/10.1172/JCI168553>
- Sannemann, L., Schild, A.-K., Altenstein, S., Bartels, C., Brosseon, F., Buerger, K., Cosma, N. C., Fliessbach, K., Freiesleben, S. D., Glanz, W., Heneka, M. T., Janowitz, D., Kilimann, I., Kobeleva, X., Laske, C., Metzger, C. D., Munk, M. H. J., Perneczky, R., Peters, O., ... Jessen, F. 2020. Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study. *Alzheimer's Research & Therapy*, 12(1), 131. <https://doi.org/10.1186/s13195-020-00701-7>
- Santiago, J. A., & Potashkin, J. A. 2021. The Impact of Disease Comorbidities in Alzheimer's Disease. *Frontiers in Aging Neuroscience*, 13. <https://doi.org/10.3389/fnagi.2021.631770>
- Scaricamazza, E., Colonna, I., Sancesario, G. M., Assogna, F., Orfei, M. D., Franchini, F., Sancesario, G., Mercuri, N. B., & Liguori, C. 2019. Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimer's disease patients: a retrospective observational study. *Neurological Sciences*, 40(7), 1377–1382. <https://doi.org/10.1007/s10072-019-03840-4>
- Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. 2021. Alzheimer's disease. *The Lancet*, 397(10284), 1577–1590. [https://doi.org/10.1016/S0140-6736\(20\)32205-4](https://doi.org/10.1016/S0140-6736(20)32205-4)
- Showraki, A., Murari, G., Ismail, Z., Barfett, J. J., Fornazzari, L., Munoz, D. G., Schweizer, T. A., & Fischer, C. E. 2019. Cerebrospinal Fluid Correlates of Neuropsychiatric Symptoms in Patients with Alzheimer's Disease/Mild

- Cognitive Impairment: A Systematic Review. *Journal of Alzheimer's Disease*, 71(2), 477–501. <https://doi.org/10.3233/JAD-190365>
- Siddappaji, K. K., & Gopal, S. 2021. Molecular mechanisms in Alzheimer's disease and the impact of physical exercise with advancements in therapeutic approaches. *AIMS Neuroscience*, 8(3), 357–389. <https://doi.org/10.3934/Neuroscience.2021020>
- Suárez-Calvet, M., Karikari, T. K., Ashton, N. J., Lantero Rodríguez, J., Milà-Alomà, M., Gispert, J. D., Salvadó, G., Minguillon, C., Fauria, K., Shekari, M., Grau-Rivera, O., Arenaza-Urquijo, E. M., Sala-Vila, A., Sánchez-Benavides, G., González-de-Echávarri, J. M., Kollmorgen, G., Stoops, E., Vanmechelen, E., Zetterberg, H., ... Vilor-Tejedor, N. 2020. Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer's continuum when only subtle changes in A β pathology are detected. *EMBO Molecular Medicine*, 12(12), 1–19. <https://doi.org/10.15252/emmm.202012921>
- Thijssen, E. H., La Joie, R., Strom, A., Fonseca, C., Iaccarino, L., Wolf, A., Spina, S., Allen, I. E., Cobigo, Y., Heuer, H., VandeVrede, L., Proctor, N. K., Lago, A. L., Baker, S., Sivasankaran, R., Kieloch, A., Kinhikar, A., Yu, L., Valentin, M. A., ... Boxer, A. L. 2021. Association of Plasma P-tau217 and P-tau181 with clinical phenotype, neuropathology, and imaging markers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. *Lancet Neurology*, 20(9), 739–752. [https://doi.org/10.1016/S1474-4422\(21\)00214-3](https://doi.org/10.1016/S1474-4422(21)00214-3). Association
- Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., Spina, S., VandeVrede, L., Chai, X., Proctor, N. K., Airey, D. C., Shcherbinin, S., Duggan Evans, C., Sims, J. R., Zetterberg, H., Blennow, K., ... Boxer, A. L. 2020. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. *Nature Medicine*, 26(3), 387–397. <https://doi.org/10.1038/s41591-020-0762-2>
- Tissot, C., Theriault, J., Pascoal, T. A., Chamoun, M., Lussier, F. Z., Savard, M., Mathotaarachchi, S. S., L. Benedet, A., Thomas, E. M., Parsons, M., Nasreddine, Z., Rosa-Neto, P., & Gauthier, S. 2021. Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, 7(1), 1–11. <https://doi.org/10.1002/trc2.12154>
- van der Lee, S. J., Wolters, F. J., Ikram, M. K., Hofman, A., Ikram, M. A., Amin, N., & van Duijn, C. M. 2018. The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study. *The Lancet Neurology*, 17(5), 434–444. [https://doi.org/10.1016/S1474-4422\(18\)30053-X](https://doi.org/10.1016/S1474-4422(18)30053-X)
- Wang, D., Huang, X., Yan, L., Zhou, L., Yan, C., Wu, J., Su, Z., & Huang, Y. 2021. The Structure Biology of Tau and Clue for Aggregation Inhibitor Design. *The Protein Journal*, 40(5), 656–668. <https://doi.org/10.1007/s10930-021-10017-6>

- Wang, J.-H., Wu, Y.-J., Tee, B. L., & Lo, R. Y. 2018. Medical Comorbidity in Alzheimer's Disease: A Nested Case-Control Study. *Journal of Alzheimer's Disease*, 63(2), 773–781. <https://doi.org/10.3233/JAD-170786>
- Wardani, N. D., Hadiati, T., & Racmawati. 2021. *BPSD (Behavioral & Psychological Symptoms Of Dementia) dan Penatalaksanaannya* (Vol. 1).
- Yan, K., He, S., Jia, X., Li, H., Liu, D., & Chen, J. 2024. *The diagnostic value of plasma phosphorylated tau 181 in Alzheimer's disease within the Chinese population: A systematic review and meta-analysis*. <https://doi.org/10.1101/2024.08.15.24312085>

